The global biopharmaceutical excipients market size is expected to reach USD 2.7 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 6.08% over the forecast period. Rapid expansion of the biopharmaceutical industry due to increasing manufacturing capacities is one of the key driving force of this market. Rise in the number of protein therapeutics coupled with the presence of a substantial number of excipients to protect these proteins from degradation is also driving the market growth.
Investigational studies that are implemented for the impact analysis of excipient variability on in vitro dissolution testing are expected to reduce the attrition rate of final products and increase the reproducibility. These studies help scientists in gaining insights on the in vivo functioning and pharmacodynamic analysis of large molecules. The market exhibits continuous need of innovative excipient technologies to prolong the in vivo effectiveness of biologics and for improvement in the product delivery. Moreover, extensive R&D for the development of raw materials that help improve yields in mammalian cell-culture processes is expected to drive the market in future.
To Get this report, click the link below:
Further key findings from the study suggest:
- Easy availability and wide usage of dextrose, sucrose, and starch in biopharmaceutical formulations has resulted in the largest revenue share of carbohydrates
- Polyols is expected to be the fastest-growing product segment in the global biopharmaceutical excipients market
- This can be attributed to increasing concerns regarding protein degradation, which can be reduced by using polyols
- North America led the global market in 2017 accounting for the largest revenue share as a result of the presence of key biopharmaceutical manufacturers in U.S.
- Emerging markets, such as India and China, are projected to be driven by the contract manufacturers operating in these regions
- Some major biopharmaceutical excipient suppliers are Merck KGaA; Roquette; Clariant; DFE Pharma; SPI Pharma, Inc.; and JRS Pharma LP
- Most of these companies are engaged in establishing partnerships with biopharmaceutical manufacturers to understand their needs and develop raw materials specific to the process and end-product
Grand View Research has segmented the global biopharmaceutical excipients market on the basis of product and region:
Biopharmaceutical Excipients Product Outlook (Volume, Tons; Revenue, USD Million, 2014 - 2025)
- Solubilizers & Surfactants/Emulsifiers
- Triglycerides
- Esters
- Others
- Polyols
- Mannitol
- Sorbitol
- Others
- Carbohydrates
- Dextrose
- Sucrose
- Starch
- Others
- Specialty Biopharmaceutical Excipients/Others
